BrainChild Bio, Inc. logo

BrainChild Bio, Inc.

brainchildbio.com

BrainChild Bio develops CAR T-cell therapies for central nervous system tumors, prioritizing pediatric brain cancers such as diffuse intrinsic pontine glioma and extending its pipeline to adult tumors including glioblastoma and brain metastases. It aims to create safe and effective treatment options for children and adults with incurable brain tumors.

Facts

Sectors
Biotechnology Research
Employees
11–50
Stage
Series A
Founders
Michael Jensen, MD

Is this your organization? Claim it

Recent coverage

Front-page news, podcasts and videos about BrainChild Bio, Inc.

See all 17

Jacob Colker announces Seattle startups score major wins: Stoke Space $1B raise, BrainChild Bio $116M, Nuance Labs $50M, Helion expands

A roundup by Jacob Colker highlights major Seattle-area tech and biotech funding and growth: Stoke Space raised $1B (now $2.3B) for reusable rockets, BrainChild Bio $116M for a CAR-T DIPG trial, General Robotics offers rapid robot deployment, Helion expands amid fusion commercialization with 800+ employees, and Nuance Labs raised $50M for multimodal AI.

By BrainChild Bio, Inc.

See all 7

BrainChild Bio to pursue multi-center Phase 2 pivotal trial of BCB-276, an autologous B7-H3 CAR T therapy for DIPG after positive FDA meeting and Phase 1 Nature Medicine data

BrainChild Bio will advance BCB-276, an autologous B7-H3–targeting CAR T-cell therapy for diffuse intrinsic pontine glioma (DIPG), into a multi-center Phase 2 pivotal trial following a positive FDA Type B meeting and supportive Phase 1 data published in Nature Medicine. The company aims to use this accelerated path toward a Biologics License Application to bring a potential treatment to children and young adults with no approved options.

People

  • Michael Jensen
    Michael Jensen Founder, Chief Scientific Officer
  • Steven Brugger Executive, Chief Executive Officer

Online

Questions about BrainChild Bio, Inc.

What is BrainChild Bio, Inc.?

BrainChild Bio, Inc. is a startup developing CAR T-cell therapies for central nervous system tumors in children and adults.

What is BrainChild Bio, Inc. known for?

BrainChild Bio, Inc. prioritizes pediatric brain cancers such as diffuse intrinsic pontine glioma, with a pipeline extending to adult tumors including glioblastoma and brain metastases.

Who are the people behind BrainChild Bio, Inc.?

Michael Jensen is founder and chief scientific officer of BrainChild Bio, Inc. Steven Brugger is chief executive officer.

Who invested in BrainChild Bio, Inc., and how much has it raised?

Members of Seattle Flow see BrainChild Bio, Inc.'s funding rounds, amounts and investors on its Funding tab. Joining is free.

How many people work at BrainChild Bio, Inc.?

BrainChild Bio, Inc. has 11–50 employees.